CN211797778U

CN211797778U - Novel osmotic pump controlled release tablet

Info

Publication number: CN211797778U
Application number: CN201922169400.6U
Authority: CN
Inventors: 郑珊
Original assignee: Guizhou Education University
Current assignee: Guizhou Education University
Priority date: 2019-12-06
Filing date: 2019-12-06
Publication date: 2020-10-30
Anticipated expiration: 2029-12-06

Abstract

The utility model provides a novel osmotic pump controlled release tablet relates to osmotic pump piece technical field, including first tablet membrane, bottom one side of first tablet membrane is provided with the pellicle, top one side of pellicle is provided with second tablet membrane, be provided with diaphragm device between first tablet membrane and the second tablet membrane, diaphragm device includes first diaphragm layer, the both sides on first diaphragm layer respectively with be fixed connection between one side of first tablet membrane and second tablet membrane, the bottom on first diaphragm layer is provided with the second diaphragm layer, the both sides on second diaphragm layer respectively with be fixed connection between one side of first tablet membrane and second tablet membrane. Solves the problems that the existing osmotic pump controlled release tablet can not well and continuously release the medicine when in use, so that the medicine can not continuously exist in the body of a patient, and the material of partial semipermeable membrane can not be well decomposed in the human body, thereby being not beneficial to the rehabilitation of the patient.

Description

Novel osmotic pump controlled release tablet

Technical Field

The utility model relates to an osmotic pump tablet field especially relates to a novel osmotic pump controlled release tablet.

Background

The osmotic pump controlled release preparation mainly comprises a medicament, a semipermeable membrane material, an osmotic pressure active substance and a pushing agent. Osmotic Pump Tablets (Osmotic Pump Tablets) are prepared by coating a semipermeable coating film formed by a layer of polymer on a tablet core and forming one or more medicine releasing pores with proper size on the coating film layer of the tablet by laser. After oral administration, water in gastrointestinal tract enters the tablet core through the semipermeable membrane, the solution in the membrane is hypertonic due to osmotic pressure active substances, and the water continues to enter the membrane due to the osmotic pressure existing outside the membrane, so that the medicinal solution or the suspended medicament is pumped out from the small hole. A commonly used semipermeable membrane material is cellulose acetate. The osmotic pressure active substance has the function of regulating the osmotic pressure in the medicine chamber, the dosage of the osmotic pressure active substance is related to the zero-order medicine release time, and sodium chloride, lactose, fructose, glucose, mannose and the like are commonly used. The pushing agent can absorb water to swell, and push the medicine in the medicine layer out of the medicine releasing pore, and high molecular weight polyethylene glycol is commonly used. In addition to the above components, suspending agent, adhesive, lubricant, wetting agent, etc. can be added into the osmotic pump tablet.

The existing osmotic pump controlled release tablet can not perform good effect of continuously releasing the medicine when in use, so that the medicine can not continuously exist in the body of a patient, and the material of partial semipermeable membrane can not be well decomposed in the human body, thereby being not beneficial to the rehabilitation of the patient.

SUMMERY OF THE UTILITY MODEL

Technical problem to be solved

Aiming at the defects of the prior art, the utility model provides a novel osmotic pump controlled release tablet, which has the advantages of good function of continuously releasing drugs and solves the problem of poor drug release effect of the existing controlled release tablet.

(II) technical scheme

In order to realize the purpose of the good function of continuously releasing the medicine, the utility model provides the following technical proposal: the utility model provides a novel osmotic pump controlled release tablet, includes first tablet membrane, bottom one side of first tablet membrane is provided with the pellicle, top one side of pellicle is provided with second tablet membrane, be provided with the diaphragm device between first tablet membrane and the second tablet membrane.

Preferably, the diaphragm device comprises a first diaphragm layer, two sides of the first diaphragm layer are fixedly connected with one side of the first tablet film and one side of the second tablet film respectively, a second diaphragm layer is arranged at the bottom of the first diaphragm layer, and two sides of the second diaphragm layer are fixedly connected with one side of the first tablet film and one side of the second tablet film respectively.

Preferably, the material of the first separator layer is a starch film, and the material of the second separator layer is a starch film enhancement layer, so that the existence time of the starch film can be increased.

Preferably, the first tablet film and the second tablet film are mainly made of gelatin, so that the stimulation effect of the medicine can be isolated, and the medicine is convenient to swallow.

Preferably, the material of the semipermeable membrane is egg membrane, which can prevent the loss of medicine and contains a large amount of natural antibiotics, collagen, protein, etc.

Preferably, a drug release hole is formed between the first tablet film and the second tablet film, and an expansion chamber is formed between the diaphragm device and the semipermeable membrane.

(III) advantageous effects

Compared with the prior art, the utility model provides a novel osmotic pump controlled release tablet possesses following beneficial effect:

the utility model discloses in, the diaphragm device and the pellicle of adoption, realize fine function that lasts to release medicine, the material of first diaphragm layer is the starch membrane, the material of second diaphragm layer is the starch membrane enhancement layer, can increase the time that the starch membrane exists, make and to last to release medicine, the material of pellicle is the egg membrane, the loss that can prevent the medicine has, contain a large amount of natural antibiotics, collagen, protein etc., reduce the time that needs the decomposition, make the inside that internal moisture enters into the expansion chamber through the pellicle, make diaphragm device upwards extrude, discharge the medicine through releasing medicine hole, treat human internal portion.

Drawings

FIG. 1 is a schematic view of the overall structure of a novel osmotic pump controlled release tablet according to the present invention;

FIG. 2 is a schematic view of the structure of the release process of the novel osmotic pump controlled release tablet provided by the present invention;

fig. 3 is a schematic structural view of a novel membrane device in an osmotic pump controlled release tablet according to the present invention.

Illustration of the drawings:

1. a first tablet film; 2. a semi-permeable membrane; 3. a second tablet film; 4. a diaphragm device; 41. a first separator layer; 42. a second membrane layer.

Detailed Description

In order to make the technical means, creation features, achievement purposes and functions of the present invention easy to understand and understand, the present invention is further described below with reference to the following embodiments.

Referring to fig. 1-3, a novel osmotic pump controlled release tablet comprises a first tablet film 1, a semipermeable membrane 2 arranged at one side of the bottom of the first tablet film 1, a second tablet film 3 arranged at one side of the top of the semipermeable membrane 2, and a diaphragm device 4 arranged between the first tablet film 1 and the second tablet film 3.

Further, the diaphragm device 4 includes a first diaphragm layer 41, two sides of the first diaphragm layer 41 are respectively and fixedly connected with one side of the first tablet film 1 and one side of the second tablet film 3, a second diaphragm layer 42 is disposed at the bottom of the first diaphragm layer 41, and two sides of the second diaphragm layer 42 are respectively and fixedly connected with one side of the first tablet film 1 and one side of the second tablet film 3.

Further, the material of the first separator layer 41 is a starch film, and the material of the second separator layer 42 is a starch film enhancement layer, so that the existence time of the starch film can be increased.

Furthermore, the first tablet film 1 and the second tablet film 3 are mainly made of gelatin, so that the stimulation effect of the medicine can be isolated, and the medicine is convenient to swallow.

Furthermore, the material of the semipermeable membrane 2 is egg membrane, which can prevent the loss of medicine and contains a large amount of natural antibiotics, collagen, protein, etc.

Furthermore, a drug release hole is formed between the first tablet film 1 and the second tablet film 3, and an expansion chamber is formed between the diaphragm device 4 and the semipermeable membrane 2.

The utility model discloses a theory of operation and use flow: through the diaphragm device 4 and the semipermeable membrane 2, a good continuous medicine release function is realized, the first diaphragm layer 41 is made of a starch film, the second diaphragm layer 42 is made of a starch film enhancement layer, the existence time of the starch film can be prolonged, continuous medicine release can be realized, the semipermeable membrane 2 is made of an egg film, the medicine loss can be prevented, a large amount of natural antibiotics, collagen, protein and the like are contained, the time required for decomposition is shortened, water in a human body enters the inside of the expansion chamber through the semipermeable membrane 2, the diaphragm device 4 is extruded upwards, the medicine is discharged through the medicine release holes, and the treatment is carried out on the inside of the human body.

It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other identical elements in a process, method, article, or apparatus that comprises the element.

Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims

1. A novel osmotic pump controlled release tablet comprises a first tablet film (1), and is characterized in that: bottom one side of first tablet membrane (1) is provided with pellicle (2), top one side of pellicle (2) is provided with second tablet membrane (3), be provided with diaphragm device (4) between first tablet membrane (1) and second tablet membrane (3).

2. The novel osmotic pump controlled release tablet of claim 1, wherein: the diaphragm device (4) comprises a first diaphragm layer (41), two sides of the first diaphragm layer (41) are fixedly connected with one sides of the first tablet film (1) and the second tablet film (3) respectively, a second diaphragm layer (42) is arranged at the bottom of the first diaphragm layer (41), and two sides of the second diaphragm layer (42) are fixedly connected with one sides of the first tablet film (1) and the second tablet film (3) respectively.

3. The novel osmotic pump controlled release tablet according to claim 2, wherein: the first membrane layer (41) is made of a starch film, and the second membrane layer (42) is made of a starch film reinforcing layer.

4. The novel osmotic pump controlled release tablet of claim 1, wherein: the first tablet film (1) and the second tablet film (3) are mainly made of gelatin.

5. The novel osmotic pump controlled release tablet of claim 1, wherein: the material of the semipermeable membrane (2) is an egg membrane.

6. The novel osmotic pump controlled release tablet of claim 1, wherein: drug release holes are formed between the first tablet film (1) and the second tablet film (3), and an expansion chamber is formed between the diaphragm device (4) and the semipermeable membrane (2).